Summary of Key Information:
Reporting Period (Quarter/Year): Q2 and Half Year ended September 30, 2026 (FY27)
Nature of Filing / Announcement: Outcome of Board Meeting - Unaudited Financial Results
Audit Opinion:
Clean (Unmodified Review Report)
Auditor’s Comment:
Statutory Auditors S.R. Batliboi & Associates LLP issued a clean limited review report. Nothing came to their attention that causes them to believe the statements contain any material misstatement.
Key Financial Highlights [Rs in millions]:
Standalone Results:
Revenue from Operations (Q2 FY27): ₹9,478.21 (vs ₹8,916.13 in Q2 FY26; +6.3% YoY)
Total Income (Q2 FY27): ₹9,687.32
Net Profit (Q2 FY27): ₹1,085.16 (vs ₹1,206.13 in Q2 FY26; -10.0% YoY)
EPS (Q2 FY27 Basic): ₹4.31 (not annualized)
Standalone Half Year FY27:
Revenue from Operations: ₹17,496.98 (vs ₹17,018.21 in H1 FY26; +2.8% YoY)
Net Profit: ₹1,802.62 (vs ₹1,900.98 in H1 FY26; -5.2% YoY)
EPS (H1 FY27 Basic): ₹7.21 (not annualized)
Other Equity (Standalone as of Sep 30, 2026): ₹56,462.56 (vs ₹43,743.36 as of Mar 31, 2026)
Cash and Cash Equivalents (Standalone as of Sep 30, 2026): ₹6,908.70 (vs ₹2,100.93 as of Mar 31, 2026)
Debt (Standalone Current Borrowings as of Sep 30, 2026): ₹3,817.34 (vs ₹7,336.80 as of Mar 31, 2026)
Consolidated Results:
Revenue from Operations (Q2 FY27): ₹15,599.74 (vs ₹12,969.88 in Q2 FY26; +20.3% YoY)
Total Income (Q2 FY27): ₹15,706.59
Net Profit (Q2 FY27): ₹1,818.37 (vs ₹1,306.06 in Q2 FY26; +39.2% YoY)
EPS (Q2 FY27 Basic): ₹7.22 (not annualized)
Consolidated Half Year FY27:
Revenue from Operations: ₹30,367.48 (vs ₹25,070.94 in H1 FY26; +21.1% YoY)
Net Profit: ₹3,618.00 (vs ₹2,432.42 in H1 FY26; +48.7% YoY)
EPS (H1 FY27 Basic): ₹14.48 (not annualized)
Other Equity (Consolidated as of Sep 30, 2026): ₹65,393.06 (vs ₹50,602.15 as of Mar 31, 2026)
Cash and Cash Equivalents (Consolidated as of Sep 30, 2026): ₹9,448.70 (vs ₹8,802.38 as of Mar 31, 2026)
Debt (Consolidated Current Borrowings as of Sep 30, 2026): ₹6,187.78 (vs ₹10,409.82 as of Mar 31, 2026)
Segment-wise Performance:
The Company operates in one reportable business segment: Pharmaceutical products including ingredients and intermediaries.
Corporate Actions:
The Company allotted 24,982,906 equity shares (face value ₹1/- each) at a premium of ₹584/- per share upon conversion of warrants. The balance subscription amount of ₹10,961.25 million was received.
Other Significant Information:
The Company incorporated two wholly owned subsidiaries:
- "TRITON FARMACEUTICA DO BRASIL LTDA" in Brazil on September 30, 2026
- "TRITON FARMACEUTICA, S.A. de C.V" in Mexico on October 22, 2026
Exceptional item for H1 FY25 and FY26 was transaction costs of ₹121.60 million related to the acquisition of Senn Chemicals AG.